Bayer Shakes Up Prostate Cancer Market

In the following video Fool contributor Maxx Chatsko updates investors on yet another treatment set to enter the quickly growing prostate cancer market. The Food and Drug Administration recently approved Xofigo, an advanced prostate cancer drug, from Bayer -- months before its PDUFA review -- for patients with castration-resistant prostate cancer who have symptomatic bone metastases and no known visceral metastatic disease.

This is amazing news for patients and yields more specific treatment for those affected by prostate cancer. It could go a long way in helping the approximately 240,000 new cases of prostate cancer that are diagnosed each year. The approval also shakes up the cancer drug market quite a bit. This is horrible news for ailing Provenge from Dendreon (NASDAQ: DNDN  ) , but also poses significant competition to Zytiga from Johnson & Johnson (NYSE: JNJ  ) and Xtandi by Medivation (NASDAQ: MDVN  ) . 

Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy by clicking here now.


Read/Post Comments (2) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On May 29, 2013, at 8:39 PM, rscurology wrote:

    I need to respectfully disagree that this is "horrible news" for Dendreon. The NCCN guidelines recommend the use of PROVENGE in asymptomatic or minimally symptomatic pts with CRPC M1 disease. Xofigo got approval for the symptomatic patient. So, many would suggest that Xofigo actually may increase PROVENGE use by making the symptomatic patient now asymptomatic, allowing PROVENGE use in a patient population that otherwise might not had ever seen the drug due to their symptoms. I agree that it is more options for the CRPC patient.

  • Report this Comment On May 29, 2013, at 10:48 PM, bhukaplan wrote:

    I think you should talk to some oncologists before making comments. The drug is good to have for patients with painful bone mets and no lymph node or other involvement. It will almost surely be used after provenge, abiraterone, enzalutamide and probably taxotere. It does not cure anybody but relieves pain and prolongs life by 4 months. I am glad to have it but it will have little or no impact on the other meds. By the way, Bayer completely screwed up the release. It can take months for nuclear medicine physicians to be licensed to use this drug

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2457410, ~/Articles/ArticleHandler.aspx, 10/20/2014 5:11:53 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement